CN111812329A - An antibody chip kit for quantitative detection of multiple tumor markers - Google Patents
An antibody chip kit for quantitative detection of multiple tumor markers Download PDFInfo
- Publication number
- CN111812329A CN111812329A CN202010739081.2A CN202010739081A CN111812329A CN 111812329 A CN111812329 A CN 111812329A CN 202010739081 A CN202010739081 A CN 202010739081A CN 111812329 A CN111812329 A CN 111812329A
- Authority
- CN
- China
- Prior art keywords
- qualitative
- microspheres
- area
- quantitative
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502707—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the manufacture of the container or its components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G01N33/575—
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/10—Integrating sample preparation and analysis in single entity, e.g. lab-on-a-chip concept
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0887—Laminated structure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Nanotechnology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
本发明涉及一种定量检测多种肿瘤标志物的抗体芯片试剂盒。将定性纳米微球和定量磁性微球结合起来,一次可以同时进行定性和定量检测,使用超声共振驱动和磁场控制结合,将定性检测和定量检测又能够区分开,且由于定性检测的用量低,定性检测不对定量检测起到影响,操作简单,稳定性好。使用不同粒径的定性微球进行定性检测,准确性好,且抗干扰能力强。使用定量检测不必针对每种肿瘤标志物进行单独的处理,适用性好;此外超声和磁场控制的结构都可以拆卸,多次使用,经济性好。
The invention relates to an antibody chip kit for quantitatively detecting multiple tumor markers. Combining qualitative nano-microspheres and quantitative magnetic microspheres, qualitative and quantitative detection can be carried out at the same time. The combination of ultrasonic resonance drive and magnetic field control can distinguish qualitative detection and quantitative detection. Due to the low dosage of qualitative detection, Qualitative detection does not affect quantitative detection, with simple operation and good stability. Qualitative detection using qualitative microspheres of different particle sizes has good accuracy and strong anti-interference ability. The use of quantitative detection does not require separate treatment for each tumor marker, and has good applicability; in addition, the structures controlled by ultrasound and magnetic fields can be disassembled and used multiple times, which is economical.
Description
技术领域technical field
本发明涉及医学检测领域,尤其涉及一种定量检测多种肿瘤标志物的抗体芯片试剂盒及其制作方法。The invention relates to the field of medical detection, in particular to an antibody chip kit for quantitatively detecting multiple tumor markers and a preparation method thereof.
背景技术Background technique
肿瘤标志物(Tumor Marker)是肿瘤细胞本身合成释放,或机体对肿瘤细胞发生反应而升高的一类物质,其主要成分为蛋白质、糖类等。肿瘤标志物存在于血液、体液、组织中,可通过生物化学、免疫学、基因组学等方法检测,可用于肿瘤的早期诊断、预测预后、疗效评价等。肿瘤标志物的异常升高可提示肿瘤的发生,但是非肿瘤性疾病也可发生肿瘤标志物的异常升高。Tumor markers are a class of substances synthesized and released by tumor cells themselves, or increased in response to tumor cells, and their main components are proteins and carbohydrates. Tumor markers exist in blood, body fluids, and tissues, and can be detected by biochemical, immunological, genomics and other methods, and can be used for early diagnosis of tumors, prediction of prognosis, and evaluation of therapeutic effects. Abnormal elevation of tumor markers may indicate tumorigenesis, but abnormal elevation of tumor markers may also occur in non-neoplastic diseases.
现有的肿瘤标志物的检测,一般都是采用流式细胞仪方法,目前又有很有研究人员基于荧光编码微球等技术检测肿瘤标志物,但是上述方式针对不同肿瘤标志物都需要单独设置对应的检测试剂才能进行定量检测,材料处理复杂,用量较大。一次检测就需要针对所有的肿瘤标志物都设置定量检测的试剂,但是实际检测中一般至多能够测出一到两种标志物。另外在实际检测中,需要快速检测时,往往还要结合CT等其他检测手段,因此肿瘤标志物一般只要检测出有哪种,浓度有多大就可以了。The existing tumor markers are generally detected by flow cytometry. At present, many researchers detect tumor markers based on technologies such as fluorescently encoded microspheres. However, the above methods need to be set separately for different tumor markers. Only the corresponding detection reagent can be quantitatively detected, the material processing is complicated, and the amount is large. One detection requires quantitative detection reagents for all tumor markers, but in actual detection, at most one or two markers can generally be detected. In addition, in actual detection, when rapid detection is required, other detection methods such as CT are often combined. Therefore, tumor markers generally only need to be detected and the concentration is sufficient.
发明内容SUMMARY OF THE INVENTION
针对上述内容,为解决上述问题提供一种定量检测多种肿瘤标志物的抗体芯片试剂盒,包括微流控芯片、超声激发器、磁控制器、不同粒径的定性纳米微球、定量磁性微球、巯基发光基团试剂、多种肿瘤标志物的抗体、荧光检测器;每一种定性纳米微球表面可修饰一种肿瘤标志物的抗体,且定性纳米微球表面可以修饰巯基发光基团;定量磁性纳米微球表面同时修饰多种肿瘤标志物抗体,且定量磁性颗粒本身具有荧光或者特征光吸收峰;In view of the above content, in order to solve the above problems, an antibody chip kit for quantitatively detecting various tumor markers is provided, including a microfluidic chip, an ultrasonic exciter, a magnetic controller, qualitative nano-microspheres of different particle sizes, quantitative magnetic Spheres, sulfhydryl luminescent group reagents, antibodies for multiple tumor markers, fluorescence detectors; the surface of each qualitative nanosphere can be modified with an antibody for one tumor marker, and the surface of qualitative nanospheres can be modified with thiol luminescent groups ;The surface of the quantitative magnetic nanospheres is modified with multiple tumor marker antibodies at the same time, and the quantitative magnetic particles themselves have fluorescence or characteristic light absorption peaks;
微流控芯片包括加样区、反应区、运输区和检测区;加样区包括试剂加样区和样品加样区,加样区连接反应区,反应区连接运输区,运输区设置有细长的运输通道,检测区设置有定性检测区和定量检测区,定性检测区的数量是多个,每个定性检测区连接在运输区的距离反应区不同距离的出口上,定量检测区设置在运输区的末尾;The microfluidic chip includes a sample addition area, a reaction area, a transport area and a detection area; the sample addition area includes a reagent addition area and a sample addition area. The sample addition area is connected to the reaction area, and the reaction area is connected to the transportation area. Long transportation channel, the detection area is equipped with qualitative detection area and quantitative detection area. The number of qualitative detection areas is multiple, and each qualitative detection area is connected to the exit of the transportation area at different distances from the reaction area. The quantitative detection area is set at the end of the transport zone;
运输区细长的运输通道内的出口包括高出口和低出口,其中低出口为连接至定性检测区的出口,高出口为连接至定量检测区的出口,其中高出口的水平位置高于低出口的水平位置,且运输区运输通道的竖直高度大于纳米微球和磁性微球的20倍;定性纳米微球和定量磁性微球在超声激发器和磁控制器的作用下被从反应区运输到检测区。The exits in the elongated transportation channel of the transportation area include high exits and low exits, wherein the low exit is the exit connected to the qualitative detection area, and the high exit is the exit connected to the quantitative detection area, wherein the horizontal position of the high exit is higher than the low exit and the vertical height of the transport channel in the transport zone is 20 times greater than that of the nanospheres and the magnetic microspheres; the qualitative nanospheres and the quantitative magnetic microspheres are transported from the reaction zone under the action of the ultrasonic exciter and the magnetic controller to the detection area.
超声激发器包括超声信号调节器和超声换能片,超声换能片的数量是多组,每组两片;超声换能片分为横向组合纵向组,一组纵向组设置在与运输区运输方向相同的前端和后端,多组横向组设置在与运输区运输方向垂直的两端,同时连接定性检测区的开口均设置在与运输区运输方向相垂直的侧面上,每个连接定性检测区的开口均设置一组横向组;The ultrasonic exciter includes an ultrasonic signal conditioner and an ultrasonic transducer. The number of ultrasonic transducers is multiple groups, with two pieces in each group; the ultrasonic transducers are divided into horizontal and vertical groups, and one group of longitudinal groups is arranged in the transport area for transportation. The front and rear ends with the same direction, multiple sets of transverse groups are arranged at the two ends perpendicular to the transportation direction of the transportation area, and the openings connecting the qualitative detection area are all arranged on the side perpendicular to the transportation direction of the transportation area. The openings of the area are set with a set of horizontal groups;
纵向组的两片换能片工作时形成移动的驻波,且纵向组的工作频率为复合频率,工作方式为扫频工作方式,推动定性纳米微球和定量磁性微球从反应区向检测区前进;横向组的工作方式是单频率,推动对应共振频率的定性纳米微球进入对应的开口内从而进入定性检测区;The two transducer sheets of the longitudinal group form moving standing waves when working, and the working frequency of the longitudinal group is the composite frequency, and the working mode is the sweeping working mode, which pushes the qualitative nano-microspheres and quantitative magnetic microspheres from the reaction area to the detection area. Forward; the working mode of the lateral group is single frequency, and the qualitative nano-microspheres corresponding to the resonance frequency are pushed into the corresponding openings to enter the qualitative detection area;
磁控制器设置在检测芯片的上下表面上,控制定量磁性微球在运输时位于运输通道的上表面,避免进入定性检测区,从而直接到达运输区的另一端进入定量检测区。The magnetic controller is arranged on the upper and lower surfaces of the detection chip, and controls the quantitative magnetic microspheres to be positioned on the upper surface of the transportation channel during transportation, so as to avoid entering the qualitative detection area, so as to directly reach the other end of the transportation area and enter the quantitative detection area.
荧光检测器检测每个定性检测区内的荧光强度,根据不同定性检测区的荧光强度对样品进行肿瘤标志物的定性分析;光检测器检测定量检测区内的荧光强度变化或者特征光吸收变化,并结合纵向组的扫频频率对样品进行肿瘤标志物的定量分析。The fluorescence detector detects the fluorescence intensity in each qualitative detection area, and performs qualitative analysis of tumor markers on the sample according to the fluorescence intensities of different qualitative detection areas; the photodetector detects the fluorescence intensity change or characteristic light absorption change in the quantitative detection area, Combined with the sweep frequency of the longitudinal group, the samples were subjected to quantitative analysis of tumor markers.
一种所述的定量检测多种肿瘤标志物的抗体芯片试剂盒的制作方法,其特征在于包括如下步骤:A manufacturing method of the antibody chip kit for quantitatively detecting multiple tumor markers, which is characterized by comprising the following steps:
微流控芯片的制作:Fabrication of microfluidic chip:
将基底、中间层和顶板使用飞秒激光进行加工,基底、中间层和顶板的材料都是PMMA,中间层的层数为两层,利用飞秒激光在中间层加工出加样区、反应区、运输区、检测的通孔,在基底和顶板上加工出安装换能片和磁控制器的安装槽,在顶板上加工出加样区的加样孔,在下方的中间层加工出连接至定性检测区的通道,在上方的中间层加工出连接至定量检测区的通道,并按顺序将基底、中间层和顶板密封粘接;The substrate, the middle layer and the top plate are processed by femtosecond laser. The materials of the substrate, the middle layer and the top plate are all PMMA. The number of layers in the middle layer is two layers. The sample addition area and the reaction area are processed in the middle layer by the femtosecond laser. , transport area, through holes for detection, process the installation grooves for the transducer and magnetic controller on the base and top plate, process the sample injection holes in the sample adding area on the top plate, and process the connection to the bottom of the middle layer. For the channel of the qualitative detection area, the channel connected to the quantitative detection area is processed on the upper middle layer, and the substrate, the middle layer and the top plate are sealed and bonded in sequence;
超声激发器和超声控制器的安装:Installation of ultrasonic exciter and ultrasonic controller:
将超声换能片安装到微流控芯片上,并使用弹性夹固定,将换能片的导线连接至超声发生器;将磁控制器安装到微流控芯片上,并将磁控制器连接至电源;Install the ultrasonic transducer on the microfluidic chip and fix it with elastic clips, and connect the wires of the transducer to the ultrasonic generator; install the magnetic controller on the microfluidic chip, and connect the magnetic controller to the power supply;
试剂的准备:Preparation of reagents:
使用现成的Fe3O4纳米颗粒,将多种不同肿瘤标志物抗体,肿瘤标志物包括AFP、CEA、CYFRA21-1、CA19-9、CA125、PSA、NSE、β-HCG等;将其对应的抗体使用DNA或者巯基化处理的方式连接至Fe3O4纳米颗粒得到定量磁性微球;Using ready-made Fe 3 O 4 nanoparticles, a variety of different tumor marker antibodies, including AFP, CEA, CYFRA21-1, CA19-9, CA125, PSA, NSE, β-HCG, etc.; The antibody is linked to Fe 3 O 4 nanoparticles by means of DNA or thiolation treatment to obtain quantitative magnetic microspheres;
使用不同粒径的SiO2微球或者聚乙烯微球,粒径分别为150nm、200nm、500nm、700nm、1100nm等,要求粒径浮动范围小于5%,作为定性纳米微球;且将定性纳米微球的表面进行活化处理,使其可以连接巯基化的荧光基团。Use SiO 2 microspheres or polyethylene microspheres with different particle sizes, the particle sizes are 150nm, 200nm, 500nm, 700nm, 1100nm, etc., and the particle size floating range is required to be less than 5%, as qualitative nano-microspheres; and qualitative nano-microspheres are used. The surface of the sphere is activated to allow the attachment of thiolated fluorophores.
在进行检测时,将每一种不同粒径的定性纳米微球和一种肿瘤标志物的抗体进行连接,连接方式可以是DNA连接方式或者巯基化连接方式,然后将其混合后进行荧光发光基团修饰;修饰后与定量磁性微球混合,混合比例定性纳米微球:定量磁性微球1:100至1:10000,使得定性检测对定量检测的影响降低;During detection, each qualitative nanosphere with different particle sizes is connected with an antibody of a tumor marker. The connection method can be DNA connection method or thiolated connection method, and then they are mixed and subjected to fluorescent luminescence. group modification; after modification, it is mixed with quantitative magnetic microspheres, and the mixing ratio of qualitative nano-microspheres: quantitative magnetic microspheres is 1:100 to 1:10000, so that the influence of qualitative detection on quantitative detection is reduced;
将混合的微球注入加样孔,将待测样品加入加样孔,使得混合的微球和待测样品进行反应,肿瘤标志物与定性纳米微球和定量磁性微球进行结合,由于定性纳米微球的量远低于定量磁性微球,所以在反应时定性纳米微球是完全反应的;The mixed microspheres are injected into the sample well, and the sample to be tested is added to the sample well, so that the mixed microspheres and the sample to be tested react, and the tumor markers are combined with the qualitative nano-microspheres and quantitative magnetic microspheres. The amount of microspheres is much lower than the quantitative magnetic microspheres, so the qualitative nano-microspheres are fully reacted during the reaction;
启动纵向组的超声换能片,进行扫频,使得所有微球沿着运输区向检测区移动;同时启动横向组,横向组的振动频率是预先设置好的,使得在横向组的驱动下没有连接肿瘤标志物的定性纳米微球可以从对应的开口进入定性检测区,而连接了肿瘤标志物的定性纳米微球由于肿瘤标志物改变了共振频率,不能被对应的横向组驱动,因此不能进入定性检测区;此时检测不同定性检测区的荧光强度,从始至终检测不到荧光强度的定性检测区说明其对应的定性纳米微球检测到了肿瘤标志物;Activate the ultrasonic transducers in the longitudinal group to sweep the frequency, so that all the microspheres move along the transport area to the detection area; at the same time, activate the transverse group. The vibration frequency of the transverse group is preset, so that there is no The qualitative nanospheres connected with tumor markers can enter the qualitative detection area from the corresponding openings, while the qualitative nanospheres connected with tumor markers cannot be driven by the corresponding lateral group because the tumor markers change the resonance frequency, so they cannot enter Qualitative detection area; at this time, the fluorescence intensity of different qualitative detection areas is detected, and the qualitative detection area where fluorescence intensity cannot be detected from beginning to end indicates that the corresponding qualitative nanospheres have detected tumor markers;
定量磁性微球在纵向组的驱动下沿着运输区移动,同时启动磁控制器,使得磁性微球沿着运输区的顶部移动,可以进入定量检测区;The quantitative magnetic microspheres move along the transport area under the driving of the longitudinal group, and at the same time, the magnetic controller is activated, so that the magnetic microspheres move along the top of the transport area and can enter the quantitative detection area;
由于纵向组是扫频方式,因此只有扫描到对应的共振频率才能驱动定量磁性微球移动,这导致进入定量检测区的磁性微球是脉冲式增加的,从而导致定量检测区的磁性微球的荧光或者特征光吸收强度间歇变化,根据间歇变化的时间点可以得到驱动定量磁性微球的共振频率,由于定性检测已经得到肿瘤标志物的种类,在根据共振频率可以反推结合到定量磁性微球表面的肿瘤标志物的浓度,不同浓度的每种肿瘤标志物对定量磁性微球共振频率的影响可以预先通过实验得到,并绘制标准曲线或者表格。Since the longitudinal group is in a frequency sweep mode, only the corresponding resonance frequency can be scanned to drive the quantitative magnetic microspheres to move, which leads to a pulsed increase of the magnetic microspheres entering the quantitative detection area, resulting in the magnetic microspheres in the quantitative detection area. The fluorescence or characteristic light absorption intensity changes intermittently, and the resonance frequency that drives the quantitative magnetic microspheres can be obtained according to the time point of the intermittent change. Since the type of tumor marker has been obtained by qualitative detection, it can be inversely bound to the quantitative magnetic microspheres according to the resonance frequency. The concentration of tumor markers on the surface and the effect of different concentrations of each tumor marker on the resonance frequency of quantitative magnetic microspheres can be obtained through experiments in advance, and a standard curve or table can be drawn.
本发明的有益效果为:本发明将定性纳米微球和定量磁性微球结合起来,一次可以同时进行定性和定量检测,使用超声共振驱动和磁场控制结合,将定性检测和定量检测又能够区分开,且由于定性检测的用量低,定性检测不对定量检测起到影响,操作简单,稳定性好。The beneficial effects of the present invention are as follows: the present invention combines qualitative nano-microspheres and quantitative magnetic microspheres, and can simultaneously perform qualitative and quantitative detection at one time, and uses the combination of ultrasonic resonance drive and magnetic field control to distinguish qualitative detection and quantitative detection. , and because the amount of qualitative detection is low, the qualitative detection does not affect the quantitative detection, the operation is simple, and the stability is good.
使用不同粒径的定性微球进行定性检测,准确性好,且抗干扰能力强。使用定量检测不必针对每种肿瘤标志物进行单独的处理,适用性好;此外超声和磁场控制的结构都可以拆卸,多次使用,经济性好。Qualitative detection using qualitative microspheres of different particle sizes has good accuracy and strong anti-interference ability. The use of quantitative detection does not require separate treatment for each tumor marker, and has good applicability; in addition, the structures controlled by ultrasound and magnetic fields can be disassembled and used multiple times, which is economical.
附图说明Description of drawings
被包括来提供对所公开主题的进一步认识的附图,将被并入此说明书并构成该说明书的一部分。附图也阐明了所公开主题的实现,以及连同详细描述一起用于解释所公开主题的实现原则。没有尝试对所公开主题的基本理解及其多种实践方式展示超过需要的结构细节。The accompanying drawings, which are included to provide a further understanding of the disclosed subject matter, are incorporated into and constitute a part of this specification. The drawings also illustrate implementations of the disclosed subject matter, and together with the detailed description serve to explain principles of implementation of the disclosed subject matter. No attempt has been made to show more structural detail than is required for a basic understanding of the disclosed subject matter and its various ways of practicing.
图1为本发明微流控芯片的结构示意图。FIG. 1 is a schematic structural diagram of a microfluidic chip of the present invention.
具体实施方式Detailed ways
本发明的优点、特征以及达成所述目的的方法通过附图及后续的详细说明将会明确。The advantages and features of the present invention and the method for achieving the stated objects will be apparent from the accompanying drawings and the following detailed description.
实施例:Example:
一种定量检测多种肿瘤标志物的抗体芯片试剂盒,包括微流控芯片、超声激发器、磁控制器、不同粒径的定性纳米微球、定量磁性微球、巯基发光基团试剂、多种肿瘤标志物的抗体、荧光检测器;每一种定性纳米微球表面可修饰一种肿瘤标志物的抗体,且定性纳米微球表面可以修饰巯基发光基团;定量磁性纳米微球表面同时修饰多种肿瘤标志物抗体,且定量磁性颗粒本身具有荧光或者特征光吸收峰;An antibody chip kit for quantitative detection of multiple tumor markers, including a microfluidic chip, an ultrasonic exciter, a magnetic controller, qualitative nano-microspheres of different particle sizes, quantitative magnetic microspheres, thiol luminophore reagents, multi- Antibodies and fluorescence detectors for various tumor markers; the surface of each qualitative nanosphere can be modified with an antibody of one tumor marker, and the surface of qualitative nanospheres can be modified with sulfhydryl luminescent groups; the surface of quantitative magnetic nanospheres can be modified at the same time Various tumor marker antibodies, and the quantitative magnetic particles themselves have fluorescence or characteristic light absorption peaks;
微流控芯片包括加样区11、反应区12、运输区13和检测区;加样区11包括试剂加样区11和样品加样区11,加样区11连接反应区12,反应区12连接运输区13,运输区13设置有细长的运输通道,检测区设置有定性检测区14和定量检测区15,定性检测区14的数量是多个,每个定性检测区14连接在运输区13的距离反应区12不同距离的出口上,定量检测区15设置在运输区13的末尾;The microfluidic chip includes a
运输区13细长的运输通道内的出口包括高出口和低出口,其中低出口为连接至定性检测区14的出口,高出口为连接至定量检测区15的出口,其中高出口的水平位置高于低出口的水平位置,且运输区13运输通道的竖直高度大于纳米微球和磁性微球的20倍;定性纳米微球和定量磁性微球在超声激发器和磁控制器的作用下被从反应区12运输到检测区。The outlets in the elongated transport channel of the
超声激发器包括超声信号调节器和超声换能片16,超声换能片16的数量是多组,每组两片;超声换能片16分为横向组合纵向组,一组纵向组设置在与运输区13运输方向相同的前端和后端,多组横向组设置在与运输区13运输方向垂直的两端,同时连接定性检测区14的开口均设置在与运输区13运输方向相垂直的侧面上,每个连接定性检测区14的开口均设置一组横向组;The ultrasonic exciter includes an ultrasonic signal conditioner and an
纵向组的两片换能片工作时形成移动的驻波,且纵向组的工作频率为复合频率,工作方式为扫频工作方式,推动定性纳米微球和定量磁性微球从反应区12向检测区前进;横向组的工作方式是单频率,推动对应共振频率的定性纳米微球进入对应的开口18内从而进入定性检测区14;The two transducers of the longitudinal group form moving standing waves when working, and the working frequency of the longitudinal group is the composite frequency, and the working mode is the sweeping working mode, which pushes the qualitative nano-microspheres and quantitative magnetic microspheres from the
磁控制器17设置在检测芯片的上下表面上,控制定量磁性微球在运输时位于运输通道的上表面,避免进入定性检测区14,从而直接到达运输区13的另一端进入定量检测区15。The
荧光检测器检测每个定性检测区14内的荧光强度,根据不同定性检测区14的荧光强度对样品进行肿瘤标志物的定性分析;光检测器检测定量检测区15内的荧光强度变化或者特征光吸收变化,并结合纵向组的扫频频率对样品进行肿瘤标志物的定量分析。The fluorescence detector detects the fluorescence intensity in each
一种所述的定量检测多种肿瘤标志物的抗体芯片试剂盒的制作方法,其特征在于包括如下步骤:A manufacturing method of the antibody chip kit for quantitatively detecting multiple tumor markers, which is characterized by comprising the following steps:
微流控芯片的制作:Fabrication of microfluidic chip:
将基底、中间层和顶板使用飞秒激光进行加工,基底、中间层和顶板的材料都是PMMA,中间层的层数为两层,利用飞秒激光在中间层加工出加样区11、反应区12、运输区13、检测的通孔,在基底和顶板上加工出安装换能片和磁控制器17的安装槽,在顶板上加工出加样区11的加样孔,在下方的中间层加工出连接至定性检测区14的通道,在上方的中间层加工出连接至定量检测区15的通道,并按顺序将基底、中间层和顶板密封粘接;The substrate, the middle layer and the top plate are processed by femtosecond laser. The materials of the substrate, the middle layer and the top plate are all PMMA.
超声激发器和超声控制器的安装:Installation of ultrasonic exciter and ultrasonic controller:
将超声换能片16安装到微流控芯片上,并使用弹性夹固定,将换能片的导线连接至超声发生器;将磁控制器17安装到微流控芯片上,并将磁控制器17连接至电源;Install the
试剂的准备:Preparation of reagents:
使用现成的Fe3O4纳米颗粒,将多种不同肿瘤标志物抗体,肿瘤标志物包括AFP、CEA、CYFRA21-1、CA19-9、CA125、PSA、NSE、β-HCG等;将其对应的抗体使用DNA或者巯基化处理的方式连接至Fe3O4纳米颗粒得到定量磁性微球;Using ready-made Fe 3 O 4 nanoparticles, a variety of different tumor marker antibodies, including AFP, CEA, CYFRA21-1, CA19-9, CA125, PSA, NSE, β-HCG, etc.; The antibody is linked to Fe 3 O 4 nanoparticles by means of DNA or thiolation treatment to obtain quantitative magnetic microspheres;
使用不同粒径的SiO2微球或者聚乙烯微球,粒径分别为150nm、200nm、500nm、700nm、1100nm等,要求粒径浮动范围小于5%,作为定性纳米微球;且将定性纳米微球的表面进行活化处理,使其可以连接巯基化的荧光基团。Use SiO 2 microspheres or polyethylene microspheres with different particle sizes, the particle sizes are 150nm, 200nm, 500nm, 700nm, 1100nm, etc., and the particle size floating range is required to be less than 5%, as qualitative nano-microspheres; and qualitative nano-microspheres are used. The surface of the sphere is activated to allow the attachment of thiolated fluorophores.
在进行检测时,将每一种不同粒径的定性纳米微球和一种肿瘤标志物的抗体进行连接,连接方式可以是DNA连接方式或者巯基化连接方式,然后将其混合后进行荧光发光基团修饰;修饰后与定量磁性微球混合,混合比例定性纳米微球:定量磁性微球1:100至1:10000,使得定性检测对定量检测的影响降低;During detection, each qualitative nanosphere with different particle sizes is connected with an antibody of a tumor marker. The connection method can be DNA connection method or thiolated connection method, and then they are mixed and subjected to fluorescent luminescence. group modification; after modification, it is mixed with quantitative magnetic microspheres, and the mixing ratio of qualitative nano-microspheres: quantitative magnetic microspheres is 1:100 to 1:10000, so that the influence of qualitative detection on quantitative detection is reduced;
将混合的微球注入加样孔,将待测样品加入加样孔,使得混合的微球和待测样品进行反应,肿瘤标志物与定性纳米微球和定量磁性微球进行结合,由于定性纳米微球的量远低于定量磁性微球,所以在反应时定性纳米微球是完全反应的;The mixed microspheres are injected into the sample well, and the sample to be tested is added to the sample well, so that the mixed microspheres and the sample to be tested react, and the tumor markers are combined with the qualitative nano-microspheres and quantitative magnetic microspheres. The amount of microspheres is much lower than the quantitative magnetic microspheres, so the qualitative nano-microspheres are fully reacted during the reaction;
启动纵向组的超声换能片16,进行扫频,使得所有微球沿着运输区13向检测区移动;同时启动横向组,横向组的振动频率是预先设置好的,使得在横向组的驱动下没有连接肿瘤标志物的定性纳米微球可以从对应的开口进入定性检测区14,而连接了肿瘤标志物的定性纳米微球由于肿瘤标志物改变了共振频率,不能被对应的横向组驱动,因此不能进入定性检测区14;此时检测不同定性检测区14的荧光强度,从始至终检测不到荧光强度的定性检测区14说明其对应的定性纳米微球检测到了肿瘤标志物;The
定量磁性微球在纵向组的驱动下沿着运输区13移动,同时启动磁控制器17,使得磁性微球沿着运输区13的顶部移动,可以进入定量检测区15;The quantitative magnetic microspheres are moved along the
由于纵向组是扫频方式,因此只有扫描到对应的共振频率才能驱动定量磁性微球移动,这导致进入定量检测区15的磁性微球是脉冲式增加的,从而导致定量检测区15的磁性微球的荧光或者特征光吸收强度间歇变化,根据间歇变化的时间点可以得到驱动定量磁性微球的共振频率,由于定性检测已经得到肿瘤标志物的种类,在根据共振频率可以反推结合到定量磁性微球表面的肿瘤标志物的浓度,不同浓度的每种肿瘤标志物对定量磁性微球共振频率的影响可以预先通过实验得到,并绘制标准曲线或者表格。Since the vertical group is in a frequency sweep mode, the quantitative magnetic microspheres can only be driven to move when the corresponding resonance frequency is scanned, which leads to the increase of the magnetic microspheres entering the
以上所述,仅为本发明的优选实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。The above are only the preferred embodiments of the present invention, but the protection scope of the present invention is not limited thereto. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention. should be included within the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010739081.2A CN111812329B (en) | 2020-07-28 | 2020-07-28 | An antibody chip kit for quantitatively detecting multiple tumor markers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010739081.2A CN111812329B (en) | 2020-07-28 | 2020-07-28 | An antibody chip kit for quantitatively detecting multiple tumor markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111812329A true CN111812329A (en) | 2020-10-23 |
| CN111812329B CN111812329B (en) | 2023-03-10 |
Family
ID=72863217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010739081.2A Active CN111812329B (en) | 2020-07-28 | 2020-07-28 | An antibody chip kit for quantitatively detecting multiple tumor markers |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111812329B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113075176A (en) * | 2021-03-17 | 2021-07-06 | 西安医学院 | Tumor marker multi-analysis device |
| CN113655218A (en) * | 2021-08-26 | 2021-11-16 | 台州安奇灵智能科技有限公司 | A Microfluidic Instant Immunoassay Based on Magnetic Nanoparticles |
| CN119322176A (en) * | 2024-12-17 | 2025-01-17 | 中国科学院杭州医学研究所 | Biochip for simultaneously detecting multiple abundance markers and application thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186465A1 (en) * | 2001-11-27 | 2003-10-02 | Kraus Robert H. | Apparatus used in identification, sorting and collection methods using magnetic microspheres and magnetic microsphere kits |
| WO2003089157A1 (en) * | 2002-04-17 | 2003-10-30 | Cytonome, Inc. | Method and apparatus for sorting particles |
| US20080160630A1 (en) * | 2006-12-29 | 2008-07-03 | Intel Corporation | Enzymatic signal generation and detection of binding complexes in stationary fluidic chip |
| US20090053688A1 (en) * | 2007-08-20 | 2009-02-26 | Allied Innovative Systems, Llc | method and device for ultrasound assisted particle agglutination assay |
| WO2009082866A1 (en) * | 2007-12-29 | 2009-07-09 | Zhanke Wang | No limited flux magnetism microglobes quantitative detecting system and its use in biomedicine |
| US20110062957A1 (en) * | 2009-09-11 | 2011-03-17 | Hewlett-Packard Development Company, L.P. | Optically integrated biosensor based on optically detected magnetic resonance |
| US20150198532A1 (en) * | 2014-01-16 | 2015-07-16 | Korea Institute Of Science And Technology | Biomarker detecting probe capable of early detection and precise quantification and use thereof |
| CN106353497A (en) * | 2016-08-18 | 2017-01-25 | 东南大学 | Multi-tumor-marker detecting platform and method based on SERS detecting technology and micro-fluidic chip |
| CN107328931A (en) * | 2017-05-16 | 2017-11-07 | 中山大学 | A kind of quick continuous detection technique based on nano-probe and magnetic micro-nano granules |
| US20180258473A1 (en) * | 2015-11-10 | 2018-09-13 | Administracion General De La Comunidad Autonoma De Euskadi | Diagnostic methods and devices |
| CN208894245U (en) * | 2018-06-26 | 2019-05-24 | 宁波奥丞生物科技有限公司 | The micro-fluidic chip of rapid quantitative detection PLGF and sFLT-1 |
| CN111007265A (en) * | 2020-01-16 | 2020-04-14 | 郑州大学 | Simoa kit of preeclampsia risk prediction marker PIGF and application thereof |
-
2020
- 2020-07-28 CN CN202010739081.2A patent/CN111812329B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030186465A1 (en) * | 2001-11-27 | 2003-10-02 | Kraus Robert H. | Apparatus used in identification, sorting and collection methods using magnetic microspheres and magnetic microsphere kits |
| WO2003089157A1 (en) * | 2002-04-17 | 2003-10-30 | Cytonome, Inc. | Method and apparatus for sorting particles |
| US20080160630A1 (en) * | 2006-12-29 | 2008-07-03 | Intel Corporation | Enzymatic signal generation and detection of binding complexes in stationary fluidic chip |
| US20090053688A1 (en) * | 2007-08-20 | 2009-02-26 | Allied Innovative Systems, Llc | method and device for ultrasound assisted particle agglutination assay |
| WO2009082866A1 (en) * | 2007-12-29 | 2009-07-09 | Zhanke Wang | No limited flux magnetism microglobes quantitative detecting system and its use in biomedicine |
| US20110062957A1 (en) * | 2009-09-11 | 2011-03-17 | Hewlett-Packard Development Company, L.P. | Optically integrated biosensor based on optically detected magnetic resonance |
| US20150198532A1 (en) * | 2014-01-16 | 2015-07-16 | Korea Institute Of Science And Technology | Biomarker detecting probe capable of early detection and precise quantification and use thereof |
| US20180258473A1 (en) * | 2015-11-10 | 2018-09-13 | Administracion General De La Comunidad Autonoma De Euskadi | Diagnostic methods and devices |
| CN106353497A (en) * | 2016-08-18 | 2017-01-25 | 东南大学 | Multi-tumor-marker detecting platform and method based on SERS detecting technology and micro-fluidic chip |
| CN107328931A (en) * | 2017-05-16 | 2017-11-07 | 中山大学 | A kind of quick continuous detection technique based on nano-probe and magnetic micro-nano granules |
| CN208894245U (en) * | 2018-06-26 | 2019-05-24 | 宁波奥丞生物科技有限公司 | The micro-fluidic chip of rapid quantitative detection PLGF and sFLT-1 |
| CN111007265A (en) * | 2020-01-16 | 2020-04-14 | 郑州大学 | Simoa kit of preeclampsia risk prediction marker PIGF and application thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113075176A (en) * | 2021-03-17 | 2021-07-06 | 西安医学院 | Tumor marker multi-analysis device |
| CN113075176B (en) * | 2021-03-17 | 2022-11-01 | 西安医学院 | Tumor Marker Multiplex Analysis Device |
| CN113655218A (en) * | 2021-08-26 | 2021-11-16 | 台州安奇灵智能科技有限公司 | A Microfluidic Instant Immunoassay Based on Magnetic Nanoparticles |
| CN119322176A (en) * | 2024-12-17 | 2025-01-17 | 中国科学院杭州医学研究所 | Biochip for simultaneously detecting multiple abundance markers and application thereof |
| CN119322176B (en) * | 2024-12-17 | 2025-03-25 | 中国科学院杭州医学研究所 | A biochip for simultaneous detection of multiple abundance markers and its application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111812329B (en) | 2023-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2864781B1 (en) | A method and a system for quantitative or qualitative determination of a target component | |
| CN111812329B (en) | An antibody chip kit for quantitatively detecting multiple tumor markers | |
| JP4716337B2 (en) | Cell detection / sorting system by flow cytometry, and detection / sorting method | |
| US8084270B2 (en) | Device for analyzing fluids | |
| US20140170674A1 (en) | Membraine-Based Assay Devices Utilizing Time-Resolved Up-Converting Luminescence | |
| JP5652393B2 (en) | Plasmon excitation sensor and assay method used for measurement method by SPFS-LPFS system | |
| US20100311186A1 (en) | Devices and methods for performing receptor binding assays using magnetic particles | |
| JP6417725B2 (en) | Analyte detection method | |
| US20210033504A1 (en) | Micro-nano particles detection system and method thereof | |
| CN112237948B (en) | Fluorescent magnetic bead micro-fluidic chip and analytical instrument thereof | |
| JP6248030B2 (en) | Analyte detection or quantification method, analyte detection or quantification kit, and lateral flow chromatographic test strip for analyte detection or quantification | |
| JP5413544B1 (en) | Antigen detection method using lectin including enzyme treatment step | |
| KR20110120790A (en) | Centrifugal force-based microfluidic device and immunoassay method using the same | |
| CN106353497A (en) | Multi-tumor-marker detecting platform and method based on SERS detecting technology and micro-fluidic chip | |
| US20060018797A1 (en) | Microfluidic separation of particles from fluid | |
| JP6677284B2 (en) | Analyte detection method and lateral flow test strip | |
| JPH0572113A (en) | Fine particle measurement method and quantitative method using fine particles | |
| CA2549094A1 (en) | System | |
| US20230384297A1 (en) | Electrothermal flow-enhanced electrochemical magneto-immunosensor | |
| JPH05312811A (en) | Biological trace component inspection device | |
| WO2008124525A1 (en) | Nanoparticles with molecular recognition elements | |
| KR20130090174A (en) | A biosensor using quenching system and a method for detecting using thereof | |
| WO2009150595A1 (en) | Parathyroid hormone assay | |
| EP2573561A1 (en) | Thyroxine immunoassay using fluorescent particles | |
| CN110514650B (en) | A chemiluminescent assay method and system and kit using the method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |